

Award Number:  
W81XWH-09-1-0285

TITLE:  
PSA Prodrug-based multimodality agents for imaging metastatic prostate cancer.

PRINCIPAL INVESTIGATOR:  
Ronnie C. Mease, Ph.D

CONTRACTING ORGANIZATION:  
Johns Hopkins University  
Baltimore MD 21218-2680

REPORT DATE:  
April 2010

TYPE OF REPORT:  
Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command  
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: (Check one)

Approved for public release; distribution unlimited

Report contains proprietary information. The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

**REPORT DOCUMENTATION PAGE**Form Approved  
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. **PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.**

<b>1. REPORT DATE</b> 30-04-2010		<b>2. REPORT TYPE</b> Annual		<b>3. DATES COVERED</b> 01 Apr 2009-31 Mar 2010	
<b>4. TITLE AND SUBTITLE</b> PSA Prodrug based Multimodality Agents for imaging metastatic prostate cancer				<b>5a. CONTRACT NUMBER</b> W81XWH-09-1-0285	
				<b>5b. GRANT NUMBER</b>	
				<b>5c. PROGRAM ELEMENT NUMBER</b>	
<b>6. AUTHOR(S)</b>  Ronnie C. Mease  Email: rmease1@jhmi.edu				<b>5d. PROJECT NUMBER</b>	
				<b>5e. TASK NUMBER</b>	
				<b>5f. WORK UNIT NUMBER</b>	
<b>7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)</b> Johns Hopkins University Baltimore MD 21218-2680				<b>8. PERFORMING ORGANIZATION REPORT NUMBER</b>	
<b>9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)</b> U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				<b>10. SPONSOR/MONITOR'S ACRONYM(S)</b>	
				<b>11. SPONSOR/MONITOR'S REPORT NUMBER(S)</b>	
<b>12. DISTRIBUTION / AVAILABILITY STATEMENT</b> Approved for Public Release; Distribution Unlimited					
<b>13. SUPPLEMENTARY NOTES</b>					
<b>14. ABSTRACT</b>  The purpose of this work is to prepare and test a series of PSA binding prodrugs which contain both a fluorescent and radioactive group which can bind to enzymatically active PSA in the vicinity of the tumor where the polar peptide portion is cleaved producing a lipophilic cleavage product which intercalates in the cell membrane of the tumor and nearby cells. In this period we made progress in the synthesis of iodinated and radioiodinated fluorescent PSA prodrugs and PSA cleavage products. In particular we were able to introduce the acid labile tributyl tin moiety needed to incorporate the radioiodine into the molecule towards the end of the synthetic route.					
<b>15. SUBJECT TERMS</b>  Synthesis, PSA prodrugs, radionuclide and fluorescence imaging					
<b>16. SECURITY CLASSIFICATION OF:</b>			<b>17. LIMITATION OF ABSTRACT</b>	<b>18. NUMBER OF PAGES</b>	<b>19a. NAME OF RESPONSIBLE PERSON</b>
<b>a. REPORT</b>	<b>b. ABSTRACT</b>	<b>c. THIS PAGE</b>			<b>19b. TELEPHONE NUMBER</b> (include area code)
U	U	U	UU	7	USAMRMC

Our hypothesis is that a Prostate Cancer imaging agent can be developed using a prodrug approach where the prodrug is a polar radiolabeled ASP dye-PSA peptide which is selectively cleaved in the extracellular fluid of PCa to release an amphiphilic (charged and lipophilic) radiolabeled ASP dye which either intercalates into the plasma membrane of nearby cells or is internalized in cellular organelles of nearby cells. The Specific Aims for this project are as follows:


*Aim 1. Synthesis of a series of iodinated and radioiodinated fluorescent PSA Prodrugs and PSA cleavage products.* The drug group will consist of (Aminostyryl)pyridinium dyes (ASP dyes) with increasing carbon chain length and increasing number of fused benzene rings and will be conjugated to selected PSA substrate peptides to form the Prodrug.


*Aim 2. Identification of Prodrugs from Aim 1. which do not bind nonspecifically to cells in-vitro but whose PSA cleavage product does bind to cells, and determination of the site of localization (plasma membrane or internal organelle) of the cleavage product.*

*Aim 3. Evaluation of promising Prodrugs from Aim 2 as agents for imaging Prostate Cancer in mice bearing PC-3 PSA+ and PC-3 PSA- tumor xenografts.*


### Body:

In this period we have concentrated on Specific Aim 1. The synthesis of iodinated and radioiodinated PSA Prodrugs and PSA cleavage products. The original proposed synthetic routes to these compounds are shown below in Schemes 1 and 2.







Notice that tributyl tin moiety which acts as the leaving group for the electrophilic iodination and radioiodination is formed early in the synthesis. Since organotin moieties are acid labile formation of this functional group early in the synthesis is probably not optimal. Therefore, we have been investigating a revised synthetic route where an alkyl vinyl tributyl tin moiety is attached to the monoalkylated aniline moiety late in the synthesis. A new proposed synthetic scheme is shown below in Scheme 3.




Progress on this route is discussed below and in Scheme 4. Commercial 4-bromo methyl benzoate compound **36** is monoalkylated to give **37** which is then reduced to alcohol **38**. The amino group of **38** is protected with t-Boc to give **39** which is then oxidized to give compound **34**. In our hands compound **34** does not readily condense with lepidine to give **35** (Scheme 3) but does condense with N-alkylated derivatives of lepidine. However, alkylation with tetraalkyl ammonium compounds like **27** and **36** has proven problematic and will be addressed further below. For investigation of this synthetic route lepidine was alkylated with 6-bromohexanoic acid ester **40** to give compound **41**. Compound **41** was then condensed with **34** to give compound **42**. Cleavage of the t-Boc group to give **43** and N-alkylation with **44** gave crude compound **45**. This demonstrates that the tributyl tin moiety which is required for radioiodination can be added near the end of this synthetic route. Longer chain analogs of **44** can be prepared as described by Groh<sup>1</sup>.





In our hands we have been unable to prepare compound **27** but have prepared related compound **46** as shown in Scheme 5 but **46** was unreactive with lepidine.



Therefore we have taken a stepwise route to the synthesis of an alkylated lepidine containing a tetraalkyl ammonium moiety within the linker. This approach is outlined in Scheme 6. Lepidine was alkylated with 1,3-dibromopropane to give compound **47**. This was then used to alkylate dimethylamino acetic acid ethyl ester compound **48** to give crude **49**. We are currently purifying this compound. We may also be able to prepare **49** by alkylating with compound **50** which was prepared by alkylating compound **48** with 1,3-dibromopropane.



Once purified we envision using compound **49** in the synthesis of iodinated and radioiodinated fluorescent PSA Prodrugs and PSA cleavage products as outlined in Scheme 7.



### Key Research Accomplishments:

1. Developed a synthetic route to the desired targets where the acid labile tributyl tin moiety needed to incorporate the radioiodine into the molecule is introduced towards the end of the synthetic route.
2. Synthesized a key intermediate containing a tetra-alkylated ammonium moiety.

### Reportable Outcomes:

1. None

**Conclusions:** We have made progress towards the synthesis of iodinated and radioiodinated fluorescent PSA Prodrugs and PSA cleavage products of Aims one and on which Aims two and three depend.

### References:

1. Groh BL E-Vinylstannanes via stereospecific transmetalation with vinylalanes facilitates by lithium salts. *Tetrahedron Letters* 32(52) 7647-7650 (1991).

**Appendices:** None

**Supporting Data:** None